Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma

Biological and Pharmaceutical Bulletin

Volumn 28, Issue 7, 2005, Pages 1286-1290

  Takahashi, Masaaki ^a   Yoshida, Masao ^a   Oki, Tsuyoshi ^a   Okumura, Naoya ^a   Suzuki, Tatsuo ^a   Kaneda, Tsuguhiro ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

HIV protease inhibitor; HPCL; Human immunodeficiency virus (HIV) 1; Therapeutic drug monitoring

Indexed keywords

ACETONITRILE; AMPRENAVIR; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; METHANOL; NELFINAVIR; PHOSPHATE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ARTICLE; CALIBRATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; ELUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; PH MEASUREMENT; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIV PROTEASE INHIBITORS; HUMANS; OXAZINES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 24944521958     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.28.1286     Document Type: Article

References (21)

1. Proust V., Toth K., Hulin A., Taburet A., Gimenez F., Singlas E., J. Chromatogr. B, 742, 453-458 (2000).
2. Yamada H., Kotaki H., Nakamura T., Iwamoto A., J. Chromatogr. B, 755, 85-89 (2001).
3. Bouley M., Briere C., Padoin C., Petitjean O., Tod M., Ther. Drug Monit., 23, 56-60 (2001).
4. Van Heeswijk R. P. G., Hoetelmans R. M. W., Harms R., Meenhorst P. L., Mulder J. W., Lange J. M. A., Beijnen J. H., J. Chromatogr. B, 719, 159-168 (1998).
5. Aymard G., Legrand M., Trichereau N., Diquet B., J. Chromatogr. B, 744, 227-240 (2000).
6. Marzolini C., Telenti A., Buclin T., Biollaz J., Decosterd L. A., J. Chromatogr. B, 740, 43-58 (2000).
7. Poirier J. M., Robidou P., Jaillon P., Ther. Drug Monit., 24, 302-309 (2002).
8. Sarasa-Nacenta M., Lopez-Pua Y., Mallolas J., Blanco J. L., Gatell J. M., Carne X., J. Chromatogr. B, 757, 325-332 (2001).
9. Dailly E., Thomas L., Kergueris M. F., Jolliet P., Bourin M., J. Chromatogr. B, 758, 129-135 (2001).
10. Hugen P. W. H., Verweij-van Wissen C. P. W. G. M., Burger D. M., Wuis E. W., Koopmans P. P., Hekster Y. A., J. Chromatogr. B, 727, 139-149 (1999).
11. Langmann P., Klinker H., Schirmer D., Zilly M., Bienert A., Richter E., J. Chromatogr. B, 735, 41-50 (1999).
12. Droste J. A. H., Verweij-van Wissen C. P. W. G. M., Burger D. M., Ther. Drug Monit., 25, 393-399 (2003).
13. Titier K., Lagrange F., Pehourcq F., Edno-Mcheik L., Moore N., Molimard M., Ther. Drug Monit., 24, 417-424 (2002).
14. Tribut O., Arvieux C., Michelet C., Chapplain J. M., Allain H., Bentue-Ferrer D., Ther. Drug Monit., 24, 554-562 (2002).
15. Remmel R. P., Kawle S. P., Weller D., Fletcher C. V., Clinical Chemistry, 46, 73-81 (2000).
16. Usami Y., Oki T., Nakai M., Sagisaka M., Kaneda T., Chem. Pharm. Bull., 51, 715-718 (2003).
17. Colombo S., Guignard N., Marzolini C., Telenti A., Biollaz J., Decosterd L. A., J. Chromatogr. B, 810, 25-34 (2004).
18. Flexner C., N. Engl. J. Med., 338, 1281-1292 (1998).
19. Poirier J. M., Robidou P., Jaillon P., Ther. Drug Monit., 21, 404-410 (1999).
20. Walson P. D., Cox S., Utkin I., Gerber N., Crim L., Brady M., Koranyi K., Ther. Drug Monit., 25, 588-592 (2003).
21. Stahle L., Moberg L., Svensson J. O., Sonnerborg A., Ther. Drug Monit., 26, 267-270 (2004).